TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04093791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective Intervention G
Description: The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Intervention I
Description: The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change.
Study: NCT02115074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatine
Description: Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01192113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV Injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV or IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV or IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV or IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
Study: NCT00771264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC Neuromodulation System
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
Study: NCT01040936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
Study: NCT05548998

Intervention type: OTHER
Intervention: General anesthesia with low fresh gas flow
Description: General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia

Intervention type: OTHER
Intervention: General anesthesia with high fresh gas flow
Description: General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini mental state examination
Description: 6 category and 30-point test to inquire patient's cognitive function

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini mental state examination
Description: 6 category and 30-point test to inquire patient's cognitive function

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: The patient's self-reported pain intensity according to a visual scale between 0 and 100

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: The patient's self-reported pain intensity according to a visual scale between 0 and 100
Study: NCT02293759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: Holmium laser enucleation of the prsotate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight laser PVP
Description: Greenlight laser (532nm) Photoslective vaporization of the prostate
Study: NCT04506398

Intervention type: PROCEDURE
Intervention: liver transplant
Description: Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.

Intervention type: PROCEDURE
Intervention: liver transplant
Description: Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
Study: NCT03292146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate 70Mg Tab
Description: Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Study: NCT00993317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: Given every 2 weeks until Week22 (SC)
Study: NCT04506398

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA
Description: Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma

Intervention type: DIAGNOSTIC_TEST
Intervention: whole exome sequencing
Description: xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.

Intervention type: DIAGNOSTIC_TEST
Intervention: whole exome sequencing
Description: xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
Study: NCT01519297

Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan
Description: 150mg orally for one dose
Study: NCT00929474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt - SJM CRT (Group 1)
Description: The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - SJM CRT (Group 2)
Description: The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
Study: NCT02788370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a conical positive expiratory pressure device
Description: The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant work load cycling test
Description: Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Constant work load cycling test
Description: Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)
Study: NCT03367559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC®
Description: Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
Study: NCT03929250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2g Centella asiatica water extract product
Description: 2g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4g Centella asiatica water extract product
Description: 4g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
Study: NCT01443494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NE
Description: norepinephine
Study: NCT03989934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Mind in Action
Description: Mindfulness program for adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Topics
Description: Health education program for adolescents
Study: NCT01899807

Intervention type: DEVICE
Group type: OTHER
Intervention: OssDsign AB
Study: NCT03817957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucoferron
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral administration
Study: NCT00898599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Inulin type fructooligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin as placebo
Study: NCT02631278

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative radiofrequency ablation
Description: Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
Study: NCT02403349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study: NCT00061373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin sodium
Description: A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin sodium
Description: A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptifibatide
Description: Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptifibatide
Description: Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
Study: NCT06618846

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastric bypass
Description: This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
Study: NCT00772122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
Study: NCT03604770

Intervention type: OTHER
Intervention: Survey & Food Diary
Description: Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
Study: NCT00380666

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT scan
Study: NCT01264848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty and/or stenting
Description: balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty and/or stenting
Description: balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
Study: NCT05284929

Intervention type: GENETIC
Intervention: A single blood sample for HLA typing
Description: Extracting of DNA from the blood sample using PCR-reaction

Intervention type: GENETIC
Intervention: A single blood sample for HLA typing
Description: Extracting of DNA from the blood sample using PCR-reaction
Study: NCT02849067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Treatment
Description: Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Group Control
Description: patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
Study: NCT01667939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) in supervised pregnancies
Description: Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
Study: NCT04007224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal oxytocin
Description: daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood
Description: patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
Study: NCT00223964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrlecit (sodium ferric gluconate complex in sucrose injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrlecit (sodium ferric gluconate complex in sucrose injection)
Study: NCT02680613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS
Description: Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS
Description: Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Travel Voucher
Description: A code for return public transportation to closest cervical cancer screening clinic included in the research.
Study: NCT00078520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 1
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2- Fixed Dose
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7
Study: NCT03341520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection [Gazyva]
Description: 7x 1000mg flat dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiation Therapy (LDRT)
Description: 2 x 2 Gy
Study: NCT04626505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (ziltivekimab)
Description: Administered s.c. once every 4 weeks for 12 weeks
Study: NCT02655874

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administered at day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Administered at day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Administered at day 180

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus-diphtheria-pertussis vaccine
Description: Administered at day 180
Study: NCT02104687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flow group
Description: After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Press group
Description: After induction, the parameters of MAP and CVP will be monitored in each of the patients.
Study: NCT01687699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Study: NCT03646539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of smartphone application (app)
Description: Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
Study: NCT01913184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKITA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKITA